|
Form of report: PDF file, around 15,000 English words
Author: Enterprise Strategy Consulting Center, CCID Consulting
Price: USD 1,700 for hardcopy version and USD 1,900 for digital version
Research field: Biomedicine, chemical drugs and so on.
Enterprises involved: Novo Nordisk, Pfizer, Merck, Sanofi-Aventis, AstraZeneca and so on.
Report Highlights
Since the 1990s, as economic globalization deepens, multinational companies have grown fast and become a major force. They are now profoundly affecting the global economic, political and social life.
In the pharmaceutical field, well-known multinational companies are now covering every corner of the world. Their economic strength, strategic innovations and technology are deeply affecting and promoting the development of enterprises in all countries.
In recent years, the Chinese economy has grown continuously and China itself has deepened its reform and opened itself further to the outside world. Particularly after China’s accession into the WTO, multinational medicine companies have adjusted to local conditions in the implementation of their R&D, human resources, investment, management and marketing strategies under the general framework of a globalization strategy.
The global medicine industry has seen an acceleration of structural adjustment. China has gained a more important position in the global market and attracting more attention from multinational medicine companies. Out of considerations for a globalization strategy, many multinational companies have set up factories and increased their investment in China in an effort to gain a favorable position in market competitions.
With their entry into and growth in China, multinational medicine companies are exerting a more important influence in China. To adapt to the special situation of economic growth in China and win in fierce market competitions, many multinational medicine companies have greatly implemented localization strategies in the fields of manufacturing, brand, human resources, marketing management, capital operations and technology R&D. Such timely and flexible strategies have become one of the important reasons for multinational medicine companies’ successes in China.
In the face of market changes and challenges, the 2006-2007 Annual Report on Investment and Operation Development of Multinational Medicine Companies in China released by CCID Consulting will help firms, investors and the industry chain more accurately grasp the growth pulses of China’s medicine industry, get a clear knowledge about their competitors, and more purposefully nurture their market competitiveness -
Rich and detailed market description data, and examine industry development trends from changes in the domestic and global software industry.
Highlight the performances of multinational medicine companies in China in 2006, and sum up their competition strategies from the dimensions of R&D scale, marketing, human resources and localization.
Make in-depth analysis of leading multinational medicine companies’ major strategic measures such as services positioning, product positioning, human resources and localization strategy.
In combination with the research conclusions about multinational medicine companies’ competition strategies in China, make recommendations to support domestic enterprises’ decision making.
Framework of the Report
Main Conclusions
Key Findings
I. Status and Trend of the Medicine Industry
(I) Global
(II) China
II. Status of Multinational Medicine Companies’ Investment and Operations in China
(I) Growth of investment
(II) Status of operations
III. Competition Strategies of Multinational Medicine Companies in China I---R&D
(I) Overall trend of international R&D
(II) Overall trend of R&D in China
IV. Competition Strategies of Multinational Medicine Companies in China II—Marketing
(I) Customer satisfaction strategy
(II) Product strategy
(III) Brand strategy
(IV) Pricing strategy
(V) Sales channels
(VI) Promotion strategy
(VII) New marketing models
V. Competition Strategies of Multinational Medicine Companies in China III— Human Resources
(I) Highly promising corporate organizational structure
(II) 5 Major incentive systems
VI. Competition Strategies of Multinational Medicine Companies in China IV---Localization
(I) R&D localization
(II) Human resources localization
(III) Localization of communication with head offices
(IV) Marketing localization
VII. Comparative Analysis of Competition Strategies of Multinational Medicine Companies in China
VIII. Recommendations from CCID Consulting
List of Tables
Comparative Analysis of Competition Strategies of Leading Multinational Medicine Companies in China
Operational Overview of the World’s Top 10 Medicine Companies, 2004-2005
The World’s Top 20 Medicine Companies, 2004-2005—By Sales Revenues
……
List of Figures
Size a of the Global Medicine Market, 2001-2006
Size a of China’s Medicine Market, 2001-2006
……
|
